Arkolith/Insider Trading/SPRB/Form 4

Ways Douglas Kirk

Interim Chief Medical Officer, DirectorSPRUCE BIOSCIENCES, INC. (SPRB) · full profile →Form 4 · filed Jan 21, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
1 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 11, 2025Option exercise(M)1K—$01K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 11, 2025Option exercise(M)1K—$04K
Dec 11, 2025Grant(A)5K—$05K
Dec 11, 2025Grant(A)266——266
Dec 11, 2025Disposed to issuer(D)266——0
Dec 11, 2025Grant(A)400——400
Dec 11, 2025Disposed to issuer(D)400——0

Transaction Codes

M
Option exercise / conversion
A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001869391-26-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML